Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia

To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia. This was a post hoc analysis of data from two 12-week, double-blind, placebo-controlled trials of nighttime (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urology (Ridgewood, N.J.) N.J.), 2006-08, Vol.68 (2), p.328-332
Hauptverfasser:	Kaplan, Steven A., Roehrborn, Claus G., Dmochowski, Roger, Rovner, Eric S., Wang, Joseph T., Guan, Zhonghong
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds - therapeutic use Biological and medical sciences Cresols - therapeutic use Delayed-Action Preparations - therapeutic use Humans Male Medical sciences Middle Aged Muscarinic Antagonists - therapeutic use Nephrology. Urinary tract diseases Phenylpropanolamine - therapeutic use Tolterodine Tartrate Urinary Incontinence - complications Urinary Incontinence - diagnosis Urinary Incontinence - drug therapy Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urination Disorders - complications Urination Disorders - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To evaluate the efficacy and safety of nighttime dosing with tolterodine extended release (TER) in men with overactive bladder (OAB) and nocturia. This was a post hoc analysis of data from two 12-week, double-blind, placebo-controlled trials of nighttime (
ISSN:	0090-4295 1527-9995
DOI:	10.1016/j.urology.2006.03.006